Eli Lilly Invests $9 Billion to Boost Production of Weight Loss Drugs

The pharmaceutical giant's historic investment aims to meet soaring demand and alleviate shortages of Zepbound and Mounjaro.

Eli Lilly commits an additional $5.3 billion to expand its manufacturing facility in Lebanon, Indiana.
The total investment of $9 billion is the largest in the company's history, aimed at increasing production of weight loss drugs Zepbound and Mounjaro.
The expansion will help address the high demand and ongoing shortages of these medications.
The Indiana site will create 200 full-time jobs and over 5,000 construction jobs during its development.
The investment reflects a broader trend of U.S. companies reshoring manufacturing to enhance supply chain resilience.